Palantir Technologies reported a near‑doubling of commercial revenue in the third quarter, pushing the share price to $170.04, a 6% daily gain that still leaves the stock 18% below its October peak. The balance of evidence points to a neutral outlook over the next two‑to‑six weeks, with low conviction because the pullback is modest, the stock lags the broader market, and the breakout math does not meet a 3‑to‑1 reward‑to‑risk ratio.
Why it matters
The earnings release on November 8 highlighted a 96% year‑over‑year increase in total revenue to $2.31 billion, driven by a 148% surge in U.S. commercial revenue to $984 million, which for the first time exceeded government revenue. That growth narrative was already priced in by the market, as reflected by a modest 6% price rise on the day despite the headline‑grabbing numbers. The broader technology sector, represented by the XLK ETF, fell 2.24% over the past five days, while the S&P 500 slipped only 0.15%, indicating that the move was more stock‑specific than sector‑driven.
Five‑day attribution shows PLTR down 4.66% versus a 2.24% decline in XLK and a 0.15% dip in the S&P 500, meaning the stock underperformed both its sector and the market. The relative weakness aligns with the assessment’s note that PLTR is lagging the S&P 500 over 50 days by –6.6%, even though it is leading XLK by +1.2% in the same window. The divergence suggests that investors are still skeptical about the sustainability of the commercial surge, perhaps because of valuation concerns.
Commentary on the stock is split. A bullish piece from Yahoo! Finance points to strong balance sheets and growth potential, while a bearish analysis in the same outlet argues that PLTR trades at 71 times forward earnings, far above peers like AMD and Nvidia, and could face forced deleveraging (Yahoo! Finance). The Guardian’s editorial warns of political risk around the NHS contract, adding a non‑financial headwind (The Guardian). Together these views illustrate that the market is weighing both the upside of commercial growth and the downside of high multiples and regulatory exposure.
Analyst consensus remains a “buy” with a mean price target of $222, but the current price sits 23.5% below that mean, indicating a sizable discount to expectations. The spread between the low ($80) and high ($273) targets is wide, reflecting uncertainty about the stock’s trajectory.
What the evidence says
On the long‑term side, PLTR remains in an uptrend: the price sits above its 40‑week average and the 52‑week high of $209.05 is still within reach, keeping the bullish thesis of a secular growth story intact. However, the stock is now 18.7% below that high and the RSI at 40 suggests a neutral momentum environment.
For the next two‑to‑six weeks, the balance of evidence leans neutral with low conviction. The assessment identifies a pullback against a weekly uptrend that is not yet stretched, a lag of –6.6% versus the S&P 500, and a modest +1.2% outperformance versus XLK. The breakout math calls for a daily close above $175 on volume above the 20‑day average; the stop is set at $161, derived from the swing‑zone low of $163.55 less a quarter of the 14‑day ATR (≈$2.55). Targets of $185.56 (SMA‑50) and $209.05 (52‑week high) give reward‑to‑risk ratios of 0.8 and 2.4 respectively, but the scenario does not meet a 3‑to‑1 payoff, so the conviction remains low.
The strongest case against a neutral reading is the valuation gap: at $170 the stock is 23.5% below the mean analyst target, yet it trades at a forward P/E of 71, implying that any further downside could trigger margin‑call pressure on leveraged holders. That risk keeps conviction from rising.
Levels that matter
The structure holds above the swing‑zone low of $163.55; a break below that would be the first crack and could signal a shift toward the trend‑ending level at $153.53, the 200‑day SMA. The weekly close below $153.53 would be the rule that changes the picture, as it would indicate the weekly trend has turned down.
The breakout level is a daily close above $175 on volume exceeding the 20‑day average. If achieved, the math gives a first target at $185.56 (the 50‑day SMA) with a reward‑to‑risk of 0.8, and a second target at $209.05 (the 52‑week high) with a reward‑to‑risk of 2.4. Because the scenario does not reach a 3‑to‑1 ratio, a price of roughly $197 would be needed to achieve that payoff, which is above the first target but below the high.
What would change the picture
A weekly close below the 200‑day SMA at $153.53 would invalidate the current neutral stance and suggest a longer‑term downtrend. A non‑price catalyst such as a major regulatory decision on the NHS contract or a new government contract win could also shift the narrative dramatically.
What to watch
- Next earnings release on February 1, 2027 – the key number will be commercial‑revenue growth versus the 148% year‑over‑year rise reported this quarter.
- Sector events: any policy shift affecting data‑center spending or AI regulation could move PLTR ahead of or behind XLK.
- Valuation: the consensus “buy” rating with a mean target of $222 versus the current price, a 23.5% discount, highlights the gap between market price and analyst expectations.